Evidence map›Paper›PMID 31463866›Full record

ArticleMetabolic brain disease2019

Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells.

Akinyinka O Alabi, Abayomi M Ajayi, Benneth Ben-Azu, Osarume Omorobge, Solomon Umukoro

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. "Methyl jasmonate: bridging plant defense mechanisms and human therapeutics".Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  3. Article
  4. Therapeutic Potential of Plant Oxylipins.International journal of molecular sciences · 2022
    Review
  5. Methyl Jasmonate: Behavioral and Molecular Implications in Neurological Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Akinyinka O AlabiDepartment of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, Olabisi Onabanjo University, Ago-Iwoye, Nigeria.
Abayomi M AjayiNeuropharmacology Unit, Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Benneth Ben-AzuNeuropharmacology Unit, Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Osarume OmorobgeNeuropharmacology Unit, Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Solomon UmukoroNeuropharmacology Unit, Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria. umusolo@yahoo.com.ORCID 0000-0003-2065-5111
University of Ibadan · NGUniversity of Port Harcourt · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Decreased tyrosine hydroxylase (TH) activity, due to degeneration of dopaminergic neurons contributes to the low dopamine content and the motor deficits that characterized Parkinson's disease (PD). This study examines the effect of methyl jasmonate (MJ), a neuroprotective bioactive compound isolated from jasminum grandiflorum, on motor functions, immunopositive cells of TH, dendritic neurons and dopamine contents in rotenone (Rot)-treated rats. Rats pretreated daily with MJ (100 mg/kg, i.p) for 21 days also received Rot (2.5 mg/kg, i.p.) 30 min after each pretreatment for every 48 h for 21 days. Motor functions were assessed on day 22. The specific brain regions of the rats were processed for determination of dopamine contents, immunopositive cells of TH, neuronal cell morphology and dendritic aborizations. Rot impaired locomotion and rearing behavior, and decreased dopamine content in the striatum, prefrontal cortex and midbrain. It further reduced the expression of TH in the substantia nigra and striatum relative to vehicle-control (p < 0.05). Histopathologic studies revealed that Rot-treated rats had degenerated neurons with pyknotic nuclei and loss of nigrostriatal neuronal cells. Rot also altered the nigrostriatal dendritic neuronal networks, decreased the dendritic length and spine density. However, pretreatment with MJ improved motor deficits, increased TH activity and dopamine contents in the specific brain regions of Rot-treated rats. MJ also attenuated the cyto-architectural distortions, loss of neuronal cells and dendritic aborizations of the striatum of Rot-treated rats. These findings suggest that MJ may reverse the motor deficits associated with PD by modifying the key pathological abnormalities involved in the disease progression.

Indexed as

AcetatesAnimalsCell ShapeCorpus StriatumCyclopentanesDendritesDopamineDopaminergic NeuronsMaleMotor SkillsNeuronsNeuroprotective AgentsOxylipinsRatsRats, WistarRotenoneAcetatesCyclopentanesDopaminemethyl jasmonateNeuroprotective AgentsOxylipinsRotenoneTyrosine 3-MonooxygenaseDendritic neuronal aborizationsMethyl jasmonateMotor deficitsRotenoneTyrosine hydroxylase

Identifiers

PMID31463866
OpenAlexW2970976320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.